Loading
companiesCompany
Shanghai Miracogen
Shanghai Miracogen is a Chinese antibody-drug conjugate developer whose HER2 conjugate MRG002 has been tested across breast, stomach, bladder and biliary cancers and whose EGFR conjugate MRG003 targets head and neck and nasopharyngeal cancer.
Also called: MiracogenShanghai Miracogen Inc.美雅珂生物
Overview
Shanghai Miracogen builds antibody-drug conjugates with site-specific conjugation and auristatin payloads. MRG002 links a HER2 antibody to monomethyl auristatin E and has been studied in HER2-positive and HER2-low breast cancer, gastric cancer, urothelial carcinoma and biliary tract cancer. MRG003 targets EGFR in nasopharyngeal and head and neck squamous carcinomas, and MRG004A targets tissue factor in pancreatic cancer.
Headquarters
Shanghai, CN
Scorecard
All companies#331of 1244 companies, score 12
- phase 3 +3
- modalities +2
- registry trials +7
0 approved, 1 in phase 3, 0 earlier, 0 targets, 11 registry studies. Formula on the scorecards page.
Type
Website
Founded
2015
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
MRG002 is an experimental investigational agent whose form is not stated in the registry from Shanghai Miracogen in phase 3 trials for gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer, with its target not yet stated publicly.
drugs
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
trials
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) CancerA Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer